<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>the akampioneer &#187; Erbitux</title>
	<atom:link href="http://akampioneer.com/tag/erbitux/feed" rel="self" type="application/rss+xml" />
	<link>http://akampioneer.com</link>
	<description></description>
	<lastBuildDate>Thu, 02 Feb 2012 19:00:15 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.1</generator>
		<item>
		<title>Food for Thought: Weekly Wrap-Up</title>
		<link>http://akampioneer.com/food-for-thought/food-for-thought-weekly-wrap-up-30.html</link>
		<comments>http://akampioneer.com/food-for-thought/food-for-thought-weekly-wrap-up-30.html#comments</comments>
		<pubDate>Mon, 15 Aug 2011 17:57:15 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Food for Thought]]></category>
		<category><![CDATA[Alex Knapp]]></category>
		<category><![CDATA[broad spectrum antivirals]]></category>
		<category><![CDATA[Der Spiegel]]></category>
		<category><![CDATA[Die ZEIT]]></category>
		<category><![CDATA[Dr. Bärbel Hüsing]]></category>
		<category><![CDATA[DRACO]]></category>
		<category><![CDATA[EMEA]]></category>
		<category><![CDATA[Erbitux]]></category>
		<category><![CDATA[FAZ]]></category>
		<category><![CDATA[flu vaccine]]></category>
		<category><![CDATA[Forbes]]></category>
		<category><![CDATA[Frankfurter Allgemeine Zeitung]]></category>
		<category><![CDATA[Fraunhofer ISI]]></category>
		<category><![CDATA[Gartner]]></category>
		<category><![CDATA[Harro Albrecht]]></category>
		<category><![CDATA[Hype Cycle Report]]></category>
		<category><![CDATA[Jackie Fenn]]></category>
		<category><![CDATA[maggot therapy]]></category>
		<category><![CDATA[Markus Grill]]></category>
		<category><![CDATA[Martina Lenzen-Schulte]]></category>
		<category><![CDATA[mc10 Inc.]]></category>
		<category><![CDATA[narcolepsy]]></category>
		<category><![CDATA[Neue Zürcher Zeitung]]></category>
		<category><![CDATA[NZZ]]></category>
		<category><![CDATA[Pandemrix]]></category>
		<category><![CDATA[Personalized Medicine]]></category>
		<category><![CDATA[printed arteries]]></category>
		<category><![CDATA[printed organs]]></category>
		<category><![CDATA[Qiagen]]></category>
		<category><![CDATA[Robert-Rössle-Klinik]]></category>
		<category><![CDATA[Roland Fischer]]></category>
		<category><![CDATA[SCI]]></category>
		<category><![CDATA[Science Citation Index]]></category>
		<category><![CDATA[scientometry]]></category>
		<category><![CDATA[Sebastian Matthes]]></category>
		<category><![CDATA[Süddeutsche Zeitung]]></category>
		<category><![CDATA[Sven Stockrahm]]></category>
		<category><![CDATA[SZ]]></category>
		<category><![CDATA[Veronika Hackenbroch]]></category>
		<category><![CDATA[Wirtschaftswoche]]></category>
		<category><![CDATA[Wolf-Dieter Ludwig]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=1205</guid>
		<description><![CDATA[Joining the recent denunciation of personalized medicine in Süddeutsche Zeitung (SZ), Der Spiegel this week follows suit. Markus Grill and Veronika Hackenbroch cite Dr. Baerbel Huesing, Coordinator of Business Unit Biotechnology and Life Sciences of Fraunhofer ISI, as saying that the concept of personalized medicine is a &#8220;battle cry&#8221; of public relations: &#8220;Whoever invented it [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/food-for-thought/food-for-thought-weekly-wrap-up-30.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Company News: Micromet&#8217;s BiTE Antibodies Overcome Cancer Cell Resistance</title>
		<link>http://akampioneer.com/company-news/company-news-micromets-bite-antibodies-overcome-cancer-cell-resistance.html</link>
		<comments>http://akampioneer.com/company-news/company-news-micromets-bite-antibodies-overcome-cancer-cell-resistance.html#comments</comments>
		<pubDate>Mon, 05 Jul 2010 07:17:03 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[antibodies]]></category>
		<category><![CDATA[BiTE]]></category>
		<category><![CDATA[BRAF]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[Erbitux]]></category>
		<category><![CDATA[KRAS]]></category>
		<category><![CDATA[life cycle management]]></category>
		<category><![CDATA[Micromet]]></category>
		<category><![CDATA[panitumumab]]></category>
		<category><![CDATA[PNAS]]></category>
		<category><![CDATA[tumor resistance]]></category>
		<category><![CDATA[Vectibix]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=451</guid>
		<description><![CDATA[In several clinical trials, antibody company Micromet has demonstrated outstanding efficacy and safety of its bispecific BiTE antibodies which come with two binding sites: one for a cancer target and a second one for a T cell. As a result, T cells are recruited and guided directly to the tumor cell, initiating cancer cell death [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-micromets-bite-antibodies-overcome-cancer-cell-resistance.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Food for Thought: Simply Obscene</title>
		<link>http://akampioneer.com/food-for-thought/food-for-thought-simply-obscene.html</link>
		<comments>http://akampioneer.com/food-for-thought/food-for-thought-simply-obscene.html#comments</comments>
		<pubDate>Thu, 10 Jun 2010 15:13:04 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Food for Thought]]></category>
		<category><![CDATA[Alimta]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Avastin]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Der Spiegel]]></category>
		<category><![CDATA[Erbitux]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[Gleevec]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hycamtin]]></category>
		<category><![CDATA[Iressa]]></category>
		<category><![CDATA[Lilly]]></category>
		<category><![CDATA[lymphoma]]></category>
		<category><![CDATA[Mab-Thera]]></category>
		<category><![CDATA[Merck KGaA]]></category>
		<category><![CDATA[Nexava]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharma Mar]]></category>
		<category><![CDATA[Rituximab]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sutent]]></category>
		<category><![CDATA[Tyverb]]></category>
		<category><![CDATA[Xeloda]]></category>
		<category><![CDATA[Yondelis]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=380</guid>
		<description><![CDATA[In a recent article (&#8220;Simply Obscene&#8221;) the influential German news magazine &#8220;Der Spiegel&#8221; (20/2010, May 17, 2010) stated the pharma industry was using &#8220;with the unscrupulousness of a stock jobber&#8221; a loophole in Germany&#8217;s highly regulated health care system to charge extremely high prices for basically useless cancer medications. In particular, the article featured Yondelis by Pharma [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/food-for-thought/food-for-thought-simply-obscene.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

